Carolinas HealthCare System

Research and Clinical Trials

Title  
ARTESIA
Brief Description  
This study aims to determine if treatment with apixaban, compared with aspirin, will reduce the risk of schemic stroke and systemic embolism in patients with device-detected sub-clinical atrial fibrillation (SCAF) and additional risk factors for stroke.
Who may be Eligible  
Patients with a permanent pacemaker or defibrillator or insertable cardiac monitor capable of detecting SCAF, with at least one episode of SCAF lasting at least 6 minutes but not more than 24 hours.
Start Date  
05/05/2016
IRB Number  
12-15-02A
Principal Investigator  
Saxonhouse, Sherry
Contact Name  
Connie

For More Information, Contact   Connie  Dellinger , RN
Phone:  (704) 355-4797  Fax:  (704) 355-7264 
Email:  SHVIClinicalResearch@carolinashealthcare.org
Address:  1001 Blythe Blvd,
MCP-M-201
Charlotte, NC 28203
Close